logo

Exclusive Market Insight

& Scientific analysis

subscribe today
  • Exclusive Posts
  • Industry Newsletters
  • Clinical Trials
  • Possible Takeovers
  • Technology of the Week
  • Stock Table
  • Therapeutic Vaccines
  • Development-Stage Firms
  • Genomics
  • Prohost Picks
  • And much more...
Trick or TradeToday’s HighlightsProhost LettersNews & CommentsImpacting NewsContact
Login

Category: Today’s Highlights

Japan approved Gilead's product Epclusa®. See Also: A collaboration agreement with Yuhan

Gilead Sciences (GILD) has news that begins with an announcement today that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved Epclusa ®  (sofosbuvir 400mg/velpatasvir 100mg). Epclusa is once-daily treatment for adults with chronic hepatitis C virus (HCV) infection with decompensated cirrhosis...

Read More

January 8, 2019

0

Unveiled Good News About Prohost Picked Biotech Stocks

 The News Prohost Was Waiting for to Post Its Special Letter Prohost has one eye on the development-stage biotech and biopharmaceutical companies' scientific fundamentals and accomplishments as well as the financial results on the revenue-generating firms. Prohost has the second...

Read More

August 8, 2019

0

Nektar's Story Has Nothing to Do with the Efficacy Or the Value of NKTR-214

Nektar Therapeutics Story Everything was going well with Nektar Therapeutics ( NKTR ) stock during the Conference call regarding the firm’s Q2 financial results. (See the firm's press release under our Impacting News column). Following the Conference call the company...

Read More

August 9, 2019

0

The FDA committee voted 19 to 1 in favor of approving Amgen's & UCB's new osteoporosis product Evenity

On January 8, 2019 the osteoporosis monoclonal antibody Evenity (romosozumab) developed by Amgen and UCB was granted approval by the Japanese Ministry of Health, Labor and Welfare for osteoporosis in patients at high risk of bone fracture. Yesterday , Amgen (AMGN)   and...

Read More

January 17, 2019

0

Lipocine's product, LPCN-1144, has promising results in decreasing the risk of NASH in non-alcoholic fatty liver disease

Lipocine (LPCN) , a specialty pharmaceutical company, announced that an approximately eight-week top-line study using LPCN 1144 in subjects with non- alcoholic fatty liver disease (NAFLD) who might have the potential to develop NASH.  Treatment results showed an absolute mean...

Read More

January 17, 2019

0

Regeneron: Successful Cure for Ebola-Infected People. Read Also: The Midday Outperforming Biotech Stocks

Regeneron Product REGN-EB3 Saving Lives Regeneron ( REGN )   announced that an independent monitoring board ended its investigational product REGN-EB3  trial after reviewing interim mortality data from 499 patients. REGN-EB3 was found superior to rival therapy from Mapp Biopharmaceuticals...

Read More

August 13, 2019

0

An Early FDA Approval of Vertex’s Cystic Fibrosis Combo Symdeko

Expected or not, we believe that the news announcing that the U.S. Food and Drug Administration (FDA) approval  Vertex’s (VRTX)  cystic fibrosis combo product  Symdeko ™  (tezacaftor/ivacaftor and ivacaftor) is good news. It is indeed excellent news for the many...

Read More

February 15, 2018

0

From Stanford: A Step on the Road Toward a Cancer Cure. From Theravance: a Worthwhile Co-Development Agreement with Janssen Biotech

A Stanford research team investigating a new immunotherapy approach, which consists of injecting tiny amounts of  two  immuno-stimulating molecules directly into the cancers themselves, announced good news. The first of the two injections contained a  CpG oligonucleotide  a short stretch...

Read More

February 7, 2018

0

Agenus fincances through Tokenization. Amgen's critics hit hard. Why BioTime could thrive on OncoCyte news

AGENUS Agenus (AGEN)  announced the upcoming launch of its Biotech Electronic Security Token (BEST);  the first digital security offering in healthcare. Tokenization enables qualified investors to directly invest in a single biotech product while preserving shareholder equity. Garo Armen, Chairman...

Read More

January 30, 2019

0

Acorda’s Attempted Rally. See Also: Amgen, Merck and AstraZeneca

Acorda (ACOR)  stock was up around 10% reaching over $28 in premarket trading. The stock is trading now around $27 with its gains oscillating between $2 – $2.20. The enthusiasm for ACOR seems to be about rumors that  Biogen (BIIB)...

Read More

January 19, 2018

0

  • Previous
  • 1
  • 2
  • ...
  • 66
  • 67
  • 68
  • ...
  • 172
  • 173
  • Next

Search ProhostBiotech

Popular Links

23andMe Holding Co (ME)Abbott Laboratories (ABT)AbbVie Inc (ABBV)AbCelleraAbeona Therapeutics (ABEO)Ablynx (ABLX)AbVitro IncAcadia (ACAD)Acceleron Pharma (XLRN)AcelRx Pharmaceuticals (ACRX).Acorda Therapeutics Inc (ACOR)Acumen Pharmaceuticals (ABOS)AdaptImmune Therapeutics (ADAP)Adaptive BiotechnologiesADC Therapeutics (ADCT)Adimab LLCAdvanced Micro Devices (AMD)Advaxis (ADXS)Adverum Biotechnologies (ADVM)Aerie Pharmaceuticals (AERI)AgenTus TherapeuticsAgenus (AGEN)AgeX Therapeutics (AGE)Agilent Technologies (A)Agilis Biotherapeutics IncAgios Pharmaceuticals (AGIO)AIM ImmunoTech (AIM)Aimmune Therapeutics (AIMT)Akari Therapeutics (AKTX)Akashi TherapeuticsAkcea Therapeutics (AKCA)Akebia Therapeutics Inc (AKBA)Akero Therapeutics (AKRO)Akous Inc (a wholly owned subsidiary of Eli Lilly Company)Alder BioPharmaceuticals (ALDR)Alexion Pharmaceuticals (ALXN)Alkermes (ALKS)Allergan Plc (AGN)Allogene TherapeuticsAllogene Therapeutics (ALLO)

Recent

AstraZeneca Product Fasenra Approved in the US for Eosinophilic Granulomatosis with Polyangiitis 

September 19, 2024

0

The U.S. FDA Approves Novartis' Kisqali® to Reduce the Risk of Recurrence in People with HR+/HER2- Early Breast Cancer

September 18, 2024

0

AstraZeneca’s Imfinzi + Imjudo Demonstrated Unprecedented Overall Survival in Advanced Liver Cancer

September 17, 2024

0

Halozyme Therapeutics Announced FDA Approval of Roche’s Tecentriq Hybreza with ENHANZE

September 13, 2024

0

Johnson & Johnson Product TREMFYA® Receives U.S. FDA Approval

September 12, 2024

0

Prohost Biotech – Exclusive Biotech Research Copyright © 2026.
Privacy Policy